1
|
Uriol E, Sierra M, Comendador MA, Fra J, Martínez-Camblor P, Lacave AJ, Sierra LM. Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictive factor. Mutagenesis 2012; 28:39-48. [PMID: 22987025 DOI: 10.1093/mutage/ges050] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Most chemotherapy treatments induce DNA damage in the exposed patients. Using the comet assay and peripheral blood mononuclear cells (PBMC), we have quantified this induced DNA damage and studied its relationship with GSTM1 and GSTT1 polymorphisms, and clinical parameters. For this purpose, 29 Caucasian women, breast cancer patients under CMF or CEF adjuvant chemotherapy were included in the study. The clinical parameters considered were (i) therapies side effects, like haematological and biochemical toxicities, (ii) prognostic and predictive factors, like hormonal receptor expression, tumour differentiation degree, sickness stage, and nodal status, and (iii) the effectiveness of the chemotherapy measured as five years relapse probability. The results were also related to the confounding factor age. Comet assay results indicate that 13 patients were characterised by absence of induced DNA strand breaks, and 16 patients presented induced DNA strand breaks along the treatment. Relationships between comet variables and clinical parameters, found with principal component analysis, correlations, one-way ANOVA and multivariate logistic regression analyses revealed that: (1) baseline levels of DNA damage are related to GSTM1 genotype and to hormonal receptor expression; (2) GSTM1 genotype also influences comet results after chemotherapy, as it does the AST level; (3) the tail moment values of the cycle 6.1 and the sickness stage might predict cancer relapse at five years: for the Stage, OR = 13.8 (IIB versus I+IIA), 95% CI 0.80-238.97, and for 6.1 cycle TM, OR = 1.3, 95%, CI 0.97-1.79, with a potential model (10* Stage (I-IIA = 0, IIB = 1) + 6.1 cycle), that has a good predictive capacity, with an area under ROC curve of 0.872 (CI 0.62-1.00). To our knowledge, this is the first time such a predictive value is found for the comet assay. Nevertheless, before the comet assay could be used as a tool for oncologists, this relationship should be confirmed in more patients, and problems of standardisation and data interpretation should be solved.
Collapse
Affiliation(s)
- E Uriol
- Área de Genética, Dpto Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33006 Oviedo, Spain
| | | | | | | | | | | | | |
Collapse
|
2
|
Muriel C, Esteban E, Martinez-Camblor P, Astudillo A, Crespo G, Pardo P, Izquierdo M, Berros JP, Gutierrez E, Lacave AJ. Predictive factors for response to systemic treatments carried out in patients with advanced renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Pardo P, Muriel C, Esteban E, Izquierdo M, Astudillo A, Martinez-Camblor P, Corral N, Crespo G, Berros JP, Lacave AJ. Prognostic factors in patients with advanced renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Sanmamed MF, Esteban E, Capelan M, Astudillo A, Crespo G, Berros JP, Muriel C, Pardo P, Izquierdo M, Gutierrez E, Fonseca PJ, Luque M, Fra J, Vieitez JM, Perez-Gracia JL, Martin-Algarra S, Lacave AJ. New molecular risk factors in germ cell tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Fonseca PJ, Vieitez JM, Turienzo E, Sanz L, Perez G, Izquierdo M, Pardo-Coto P, Frunza M, Gutierrez Restrepo E, Lacave AJ. A phase II study with perioperative modified docetaxel, cisplatin, and capecitabine (mDCX) in resectable gastroesophageal adenocarcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Muriel C, Esteban E, Martinez-Camblor P, Astudillo A, Crespo G, Pardo P, Izquierdo M, Berros J, Gutierrez E, Lacave AJ. Prognostic factors for response to systemic treatments carried out in patients with advanced renal carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
369 Background: The analysis of predictive factors of response could help to select those patients with advanced renal cell carcinoma (RCC) who would be good candidates for systemic treatments Methods: The expression of several biomarkers was retrospectively analysed by immunohistochemistry (IHC), as well as 2 analytical variables: thrombocytosis and neutrophilia, in 135 patients with advanced RCC treated with cytokines (CK) and/or biological agents and was correlated to the response. Results: 67 patients were treated only with biological agents and 68 with CK (23 treated also with biological agents). Univariate statistical analysis: HIF-1alpha did not correlate significantly with the response to these drugs. The overexpression of ACIX was associated to a larger response (%) to biological agents such as sunitinib (65.9 vs. 16.7 p<0.001) or sorafenib (61.9 vs 0 p=0.007), and CK (22.6 vs. 0 p=0.038). PTEN showed a predictive value for response (%) to sunitinib (70.8 vs. 34.1 with PTEN negative p=0.005). p21 was associated to a lower response (%) with sunitinib (35.9 vs. 65.4 with p=0.025). Thrombocytosis was not significantly associated with the response (%) to biological agents, although it was associated to CK (0 vs. 20 without thrombocytosis p=0.017). Neutrophilia correlated with a smaller response to biological agents (29.6 vs. 57.5 without neutrophilia, p=0.045), although it did not associate with a response to CK. In the multivariate analysis, overexpression of ACIX was an independent predictor of a larger response to biological agents and CK with an OR of 8,773 (p<0.001). Conclusions: Our findings prove the usefulness of ACIX to select patients with advanced RCC candidates to receive systemic treatment. PTEN and p21 could be important in the prediction of response to sunitinib. Thrombocytosis and neutrophilia appear to relate to the response to CK and biological agents respectively. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Muriel
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - E. Esteban
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - P. Martinez-Camblor
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - A. Astudillo
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - G. Crespo
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - P. Pardo
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - M. Izquierdo
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - J. Berros
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - E. Gutierrez
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - A. J. Lacave
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| |
Collapse
|
7
|
Muriel C, Esteban E, Astudillo A, Martinez-Camblor P, Corral N, Crespo G, Berros J, Fonseca PJ, Luque M, Lacave AJ. Prognostic factors in patients with advanced renal carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
391 Background: A retrospective cohort of 135 patients with advanced RCC treated with biological agents and/or cytokines (CK) was analysed between July 1996 and February 2010. Methods: The expression of several biomarkers by immunohistochemistry and 2 analytical variables: thrombocytosis and neutrophilia were analysed and were correlated with prognosis. Results: 67 patients were treated only with biological agents and 68 with CK (23 received also biological agents). The univariate statistical analysis showed that the enhanced expression of HIF-1alpha correlated with a poor prognosis in patients treated with sunitinib (PFS was 5.4 vs. 13.4 months in those with low expression, p=0.001). The overexpression of ACIX was associated to a better prognosis in patients that received biological agents (PFS was 18.3 vs. 5.2 months in those with decreased expression, p<0.001; OS was 32.1 vs. 7.8 months, p<0.001), including sunitinib (PFS was 16.8 vs. 5.5 months, p<0.001), sorafenib (PFS was 8 vs 3.5 months, p<0.001)) and CK (PFS was 6.3 vs. 2.7 months, p=0.003; OS was 32.9 vs. 5.9 months, p=0.001). Positive PTEN was related to a good prognosis in patients treated with sunitinib (PFS was 15.1 vs. 6.5 months, p=0.003) and CK (PFS was 7.5 vs. 3.8 months, p=0.037, OS was 13.7 vs 7.9 months, p=0.039). The increased expression of p21 was related to a poor prognosis in patients that received biological agents (PFS was 5.9 vs. 16.8 months with high expression, p=0.024), including sunitinib (PFS was 6.2 vs 18.9 months, p<0.001), sorafenib (PFS was 4 vs 9 months, p=0.013) and CK (PFS was 3.9 vs. 7.5 months, p<0.001). Thrombocytosis was related to a poor prognosis in patients treated with CK (PFS was 2.6 vs. 5.1 months p=0.017; OS was 5.9 vs. 14.3 months p=0.010). Neutrophilia was related to a poor prognosis in patients that received CK (PFS was 2.6 vs. 5.7 months, p=0.019; OS was 5.9 vs. 12.8 months, p=0.035). In the multivariate analysis, the overexpression of ACIX was a favorable prognostic factor independent of PFS with a HR of 0.107 (p<0.001) and OS with a HR of 0.055 (p<0.001). Conclusions: Our experience has suggested the utility of de HIF-1alpha, ACIX, PTEN, p21, thrombocytosis and neutrophilia as prognostic factors in patients with advanced RCC. ACIX has shown to be an independent prognostic factor. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Muriel
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - E. Esteban
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - A. Astudillo
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - P. Martinez-Camblor
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - N. Corral
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - G. Crespo
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - J. Berros
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - P. J. Fonseca
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - M. Luque
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| | - A. J. Lacave
- Hospital Universitario Central de Asturias-IUOPA, Oviedo, Asturias, Spain; Asturias Central University Hospital, Oviedo, Asturias, Spain; Universidad de Oviedo, Oviedo, Spain
| |
Collapse
|
8
|
Vieitez J, J Fonseca P, Llaneza A, Avello N, Fernandez de Sanmamed M, Gutierrez Restrepo E, Muriel C, Sotomayor FS, Lacave AJ. Serum carcinoembryonic antigen (CEA) in the management of advanced colorectal cancer (ACRC) treated with CAPIRI plus bevacizumab. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Pardo-Coto P, Esteban E, Astudillo A, Gracia J, Corral N, Berros J, Izquierdo M, Muriel C, de Sanmamed MF, Lacave AJ. Role of the p38αMAPK in the prognosis and prediction of response to neoadjuvant chemotherapy in locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Crespo G, Sierra M, Losa R, Villanueva N, Fra J, Fonseca PJ, Fernández Y, Capelán M, Berros JP, Lacave AJ. A phase I study of pegylated liposomal doxorubicin + gemcitabine in a fixed dose-rate infusion for the treatment of patients with recurrent ovarian cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
García AG, Esteban E, Girón CG, Maroto P, Andrés R, Canelas A, Caballido J, Carles J, Espinosa E, Lacave AJ. Observational study in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2 (rIL-2). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4603 Background: Patients with metastatic renal cell carcinoma have a poor prognosis, including those with pulmonary metastases (PMRCC). The objective of this study was to obtain efficacy and safety data on inhaled rIL-2 used in clinical practice in PMRCC patients. Methods: Data provided from 107 PMRCC patients from 48 centres in Spain and 6 in Portugal, treated with inhaled rIL-2 between 2000 and 2005 were evaluated. Data were analyzed by ITT, considering a valuable patient when receiving the first dose of inhaled rIL-2. The treatment schedule was: 3 cycles of 36 MIU rIL-2 per day for 5 days/week for 12 weeks (with one week treatment free between cycles) in Spain and for 3 weeks (out of each 4 weeks) for 12 weeks in Portugal. Efficacy was assessed by best response following each treatment cycle and overall (WHO criteria). The Kaplan-Meier method was used to estimate progression free survival (PFS) and overall survival (OS) that were measured from the time of administration of the first dose of inhaled rIL-2 until progression or death. Safety data were analysed using descriptive statistics, with toxicities expressed as number of weeks in which each toxicity was reported by cycle and by grade. Results: After 1902 treatment weeks administered (median 17.8), the overall objective response rate (complete and partial response,) was 12.2% (95% CI: 6.0–18.4) and a stable disease rate of 22.45% (95% CI: 14.5–30.3). Median PFS and OS were 3.72 (95% CI: 2.86–4.57) and 18.5 (12.69– 23.61) months, respectively. Non-haematological toxicities were the most notable adverse events observed, especially in terms of cough (20.4% of weeks) and fatigue (4.4%) being grade 1 or 2 in severity and reversible by removing the treatment in all cases. Conclusions: This study provides data of efficacy and mild toxicity of inhaled rIL-2. On the basis of these findings inhaled rIL-2 might be considered as an alternative to its systemic administration to treat patients with PMRCC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. G. García
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - E. Esteban
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - C. G. Girón
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - P. Maroto
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - R. Andrés
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - A. Canelas
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - J. Caballido
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - J. Carles
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - E. Espinosa
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| | - A. J. Lacave
- Hospital Reina Sofía, Córdoba, Spain; Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Hospital Santa Cruz y San Pablo, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Hospital San Bernardo, Setubal, Portugal; Clínica Puerta de Hierro, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Madrid, Spain
| |
Collapse
|
12
|
Fernández Y, Vieitez JM, Fra J, Palacio I, Mareque B, Uña E, Buesa JM, Lacave AJ. Capecitabine plus gemcitabine in heavily pre-treated colorectal cancer. Results of an exploratory study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - J. Fra
- Hospital Central de Asturias, Oviedo, Spain
| | - I. Palacio
- Hospital Central de Asturias, Oviedo, Spain
| | - B. Mareque
- Hospital Central de Asturias, Oviedo, Spain
| | - E. Uña
- Hospital Central de Asturias, Oviedo, Spain
| | | | | |
Collapse
|
13
|
Esteban E, Vieitez J, Villanueva N, Fra J, Mareque B, Uña E, Lacave AJ. Experience with the implant of vascular access devices by medical oncologist and in non-surgical scenery. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Esteban
- Hospital Central de Asturias, Oviedo, Asturias, Spain
| | - J. Vieitez
- Hospital Central de Asturias, Oviedo, Asturias, Spain
| | - N. Villanueva
- Hospital Central de Asturias, Oviedo, Asturias, Spain
| | - J. Fra
- Hospital Central de Asturias, Oviedo, Asturias, Spain
| | - B. Mareque
- Hospital Central de Asturias, Oviedo, Asturias, Spain
| | - E. Uña
- Hospital Central de Asturias, Oviedo, Asturias, Spain
| | - A. J. Lacave
- Hospital Central de Asturias, Oviedo, Asturias, Spain
| |
Collapse
|
14
|
Vieitez JM, Girón CG, Madroñal C, Fernandez Y, Lastras E, Modolell A, Fra J, Julia C, Yglesias JM, Lacave AJ. Definitive results of a phase II study with carboplatin (CBDCA) plus etoposide (VP16) and sequential topotecan in small cell lung cancer (SCLC). (an INTER-GON trial). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. M. Vieitez
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - C. G. Girón
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - C. Madroñal
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - Y. Fernandez
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - E. Lastras
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - A. Modolell
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - J. Fra
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - C. Julia
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - J. M. Yglesias
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| | - A. J. Lacave
- Hospital Central de Asturias, Oviedo, Spain; Hospital General Yagüe, Burgos, Spain; Instituto Oncológico Corachán, Barcelona, Spain
| |
Collapse
|
15
|
Pfisterer J, Plante M, Vergote I, Du Bois A, Wagner U, Hirte H, Lacave AJ, Stähle A, Kimmig R, Eisenhauer E. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Pfisterer
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - M. Plante
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - I. Vergote
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - A. Du Bois
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - U. Wagner
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - H. Hirte
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - A. J. Lacave
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - A. Stähle
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - R. Kimmig
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| | - E. Eisenhauer
- AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Tübingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, München, Germany; NCIC CTG, Kingston, ON, Canada
| |
Collapse
|
16
|
Esteban E, González de Sande L, Fernández Y, Corral N, Fra J, Muñiz I, Vieitez JM, Palacio I, Fernández JL, Estrada E, Lacave AJ. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003; 14:1640-7. [PMID: 14581272 DOI: 10.1093/annonc/mdg456] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Docetaxel and paclitaxel have activity in the second-line treatment of non-small-cell lung cancer (NSCLC), and can be administered as weekly schedules. This phase II randomised study was designed to test the efficacy and toxicity of both taxanes in patients with NSCLC previously treated with platinum-based chemotherapy. PATIENTS AND METHODS Patients (n = 71) with documented NSCLC were randomised to receive docetaxel (n = 35 patients; 36 mg/m(2)) or paclitaxel (n = 36 patients; 80 mg/m(2)) as a 1 h weekly infusion for 6 weeks followed by a 2-week rest. The cycles were repeated until disease progression or non-acceptable toxicities occurred. RESULTS Treatment achieved partial response of one versus five patients, median time-to-progression of 74 versus 68 days, and overall survival of 184 versus 105 days, with docetaxel and paclitaxel, respectively. The most common non-haematological toxicities were (docetaxel versus paclitaxel): grade 3/4 pulmonary toxicity in seven versus one patient; grade 2/3 diarrhoea in nine versus five; and grade 3/4 haematological toxicities occurred in two versus four patients. There were no treatment-related deaths. CONCLUSIONS Docetaxel and paclitaxel administered weekly have discrete efficacy in patients with NSCLC previously treated with platinum-based chemotherapy. The higher non-haematological toxicity of docetaxel, particularly pulmonary toxicity and diarrhoea, is of concern and warrants further investigation.
Collapse
Affiliation(s)
- E Esteban
- Servicio de Oncología Médica, Hospital Central de Asturias, Oviedo, Asturias, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Esteban E, Modollel A, González de Sande L, Palacio I, Muñiz I, Fernández Y, Corral N, Fra J, Sala M, Vieitez JM, Estrada E, Lacave AJ. Combination of Docetaxel, Epirubicin and Vinorelbine Administered Every 2 Weeks as First-line Therapy in Patients with Metastatic Breast Cancer: A Dose-finding Study. Breast Cancer Res Treat 2003; 80:257-65. [PMID: 14503798 DOI: 10.1023/a:1024985309383] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
AIMS To assess efficacy and optimum combination dosage of intravenous docetaxel (T), epirubicin (E) and vinorelbine (N) administered every 2 weeks and without colony stimulating factor (CSF) support in patients with metastatic breast cancer (MBC). PATIENTS AND METHOD Patients (n = 5 1) with MBC were consecutively assigned to four different dose levels (DL) to receive (in mg/m2): Level I = T35 + E30 + N25; Level II = T30 + E30 + N25; Level III = T30 + E25 + N25; and Level IV = T25 + E25 + N25. Consecutive cycles were delayed if absolute neutrophil and/or platelet counts fell below 1.5 x 10(9) and 100 x 10(9) l(-1), respectively. Treatment at a given dose level was suspended if 33% or more of patients included in a given cohort had unacceptable toxicity. RESULTS The patients evaluable for toxicity (n = 48) received 448 cycles (median 9; range 1-23). There was neutropenia G 3-4 in 30 patients (63%) with fever in 3 (6%). The G 2-3 non-hematological toxicities were alopecia in 39 patients (81%), mucositis in 11 (23%), and nausea/vomiting in 8 (17%). There were no toxic deaths. Treatment delay or dose reduction after first cycle occurred in > or = 30% of patients treated in all DLs, except the fourth. Objective response was achieved in 29 of the 47 evaluable patients (58%; 95% CI: 50-66). The median duration of response, time-to-progression and overall survival were 13, 11 (range 8-14) and 20 (range 16-24) months, respectively. CONCLUSION The combination of docetaxel, epirubicin and vinorelbine without CSF support ought not to exceed 25 mg/m2 every 2 weeks. The efficacy is no greater than other existing regimens for first-line treatment of MBC.
Collapse
Affiliation(s)
- Emilio Esteban
- Servicio de Oncología Médica, Hospital Central de Asturias, Oviedo, Asturias, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
van Rijswijk REN, Vermorken JB, Reed N, Favalli G, Mendiola C, Zanaboni F, Mangili G, Vergote I, Guastalla JP, ten Bokkel Huinink WW, Lacave AJ, Bonnefoi H, Tumulo S, Rietbroek R, Teodorovic I, Coens C, Pecorelli S. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). Eur J Cancer 2003; 39:481-7. [PMID: 12751379 DOI: 10.1016/s0959-8049(02)00740-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Carcinosarcomas of the female genital tract are highly malignant tumours composed of carcinomatous and sarcomatous elements. In the past, these tumours were frequently treated as sarcomas. However, a number of arguments, including the sensitivity of these tumours to platinum-based chemotherapy, suggest that these tumours behave more like poorly differentiated carcinomas. The European Organization for Research and Treatment of Cancer (EORTC) Gynaecological Cancer Group therefore decided to perform a prospective phase II study in patients with advanced or metastatic carcinosarcoma with an approach such as that used in gynaecological carcinomas. Eligible patients could have primary or recurrent disease, but prior radiotherapy or chemotherapy was not allowed. The treatment plan recommended upfront debulking, followed by chemotherapy with cisplatin, ifosfamide and doxorubicin. Patients who could be debulked to non-measurable disease remained eligible for the study, but the response assessment was restricted to patients who had measurable disease before the start of chemotherapy. A total of 48 patients (39 primary disease, 9 recurrent disease) were registered, 41 of them being eligible. In 9 patients, all macroscopic lesions could be removed, 32 patients were left with residual disease and were assessable for response. The overall response rate was 56%: a complete response (CR) was observed in 11 (34%) patients and partial response (PR) in 7 (22%) patients. No change occurred in 5 patients and progression in 2 patients. In 7 patients, response could not be assessed. Median survival for all of the 41 eligible patients was 26 months. Severe leucopenia and thrombocytopenia were common and necessitated dose reductions or delays in 60% of patients. From a clinical point of view, the most severe non-haematological toxicity was renal dysfunction, and one patient died of this complication in the absence of disease progression. The results of this study are in-line with the hypothesis that carcinosarcomas are chemosensitive, in particular for the currently investigated regimen. The treatment also included upfront cytoreduction when feasible. Considering the observed toxicities, alternative platinum-based regimens with more favourable toxicity profiles should be explored.
Collapse
Affiliation(s)
- R E N van Rijswijk
- Department of Hematology/Oncology, University of Maastricht, P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg MEL, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TAW, Ploch E, Beex LVA, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JEGM, Teodorovic I, Coens C, Vergote I, Vermorken JB. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14:441-8. [PMID: 12598351 DOI: 10.1093/annonc/mdg112] [Citation(s) in RCA: 175] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. PATIENTS AND METHODS Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m(2) alone or CDDP 50 mg/m2 added to DOX 60 mg/m2, every 4 weeks. RESULTS A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36 % versus 12%). The combination DOX-CDDP provided a significantly higher response rate than single agent DOX (P <0.001). Thirty-nine patients (43%) responded on DOX-CDDP [13 complete responses (CRs) and 26 partial responses (PRs)], versus 15 patients (17%) on DOX alone (8 CR and 7 PR). The median overall survival (OS) was 9 months in the DOX-CDDP arm versus 7 months in the DOX alone arm (Wilcoxon P = 0.0654). Regression analysis showed that WHO performance status was statistically significant as a prognostic factor for survival, and stratifying for this factor, treatment effect reaches significance (hazard ratio = 1.46, 95% confidence interval 1.05-2.03, P = 0.024). CONCLUSIONS In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status.
Collapse
|
20
|
Vieitez JM, Valladares M, Gracia M, Gonzalez-Barón M, Martín G, Mel JR, Rodríguez R, Constenla M, Gómez Aldavarí JL, Domínguez S, Dorta J, García-Girón C, López R, Sevilla I, Esteban E, Antón LM, Peláez I, López E, Lacave AJ. Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer. Lung Cancer 2003; 39:77-84. [PMID: 12499098 DOI: 10.1016/s0169-5002(02)00387-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
PURPOSE To evaluate the efficacy and tolerability of paclitaxel, carboplatin and etoposide when administered in combination to previously-untreated small-cell lung cancer (SCLC) patients. PATIENTS AND METHODS Patients (n=95) with limited-stage disease (LSD; n=45) or extensive-stage disease (ESD; n=50) from 14 Spanish hospitals were entered into the study. Etoposide was administered 80 mg/m(2)/day intravenous (i.v.) on days 1, 2 and 3, paclitaxel 175 mg/m(2) i.v. on day 3 and carboplatin area-under-the-concentration-time-curve=6; i.v. on day 3, of a 3-week cycle, and repeated for up to 6 cycles. RESULTS The overall response (OR) rate was 74% (n=70; 32 complete, 38 partial). Although the OR in LSD and ESD patients was similar (73 vs 74%, respectively), the percentage complete response was significantly higher among the former (49 vs 20%). The main toxicities were grade 3-4 neutropenia and febrile neutropenia (62 and 18%, respectively) and there were 3 toxic deaths. Other toxicities were rare or easily manageable. Disease-free survival and overall survival rates at 1 year were 53 and 70% in LSD and 18 and 39% in ESD patients, respectively. CONCLUSION The results indicate that the combination of paclitaxel, etoposide and carboplatin has an anti-tumour activity in SCLC that is comparable to other combination regimens, and is well tolerated.
Collapse
Affiliation(s)
- J M Vieitez
- Department of Medical Oncology, Hospital Central de Asturias, C/Julian Claveria, s/n, 33006 Oviedo, Asturias, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Wagenaar HC, Pecorelli S, Vergote I, Curran D, Wagener DJ, Kobierska A, Bolis G, Bokkel-Huinink WT, Lacave AJ, Madronal C, Forn M, de Oliveira CF, Mangioni C, Nooij MA, Goupil A, Kerbrat P, Marth CH, Tumolo S, Herben MG, Zanaboni F, Vermorken JB. Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer. EUR J GYNAECOL ONCOL 2002; 22:187-93. [PMID: 11501769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
OBJECTIVE To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. METHODS The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. RESULTS Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. CONCLUSION The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.
Collapse
Affiliation(s)
- H C Wagenaar
- Department of Gynecology, Leiden University Medical Center, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Wagenaar HC, Pecorelli S, Mangioni C, van der Burg ME, Rotmensz N, Anastasopoulou A, Zola P, Veenhof CH, Lacave AJ, Neijt JP, van Oosterom AT, Einhorn N, Vermorken JB. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer 2001; 37:1624-8. [PMID: 11527687 DOI: 10.1016/s0959-8049(01)00178-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The aim of this study was to investigate the tumour response rate and toxicity of a combination chemotherapy consisting of mitomycin-C and cisplatin in patients with disseminated squamous-cell carcinoma of the uterine cervix. Chemotherapy consisted of mitomycin, 6 mg/m(2) intravenously (i.v.), and cisplatin, 50 mg/m(2) given i.v., both administered on day 1 of each cycle. The regimen was repeated at 4-weekly intervals. Mitomycin-C/cisplatin were used to treat 33 evaluable patients aged 29-67 years (median: 50 years). All patients except 1 had previously been treated with either surgery, radiation or both. At the initiation of chemotherapy, 8 patients had loco-regional and disseminated disease and 25 women had only distant metastases. The overall response rate was 42% (95% confidence interval (CI): 26-61%). Five complete and nine partial responses were observed with a median duration of response of 7.9 months (95% CI: 3.7-23.5 months). 9 patients had stable disease and 10 developed progressive disease during mitomycin-C/cisplatin-treatment. World Health Organization (WHO) grade III/IV side-effects were documented in 15 women, of whom 10 had gastro-intestinal toxicity, 3 had haematological toxicity, 1 had alopecia and 1 developed an allergic reaction to cisplatin. There were neither drug-related deaths nor severe or irreversible renal or hepatic dysfunction or peripheral neuropathy. The median progression-free survival was 5.0 months (95% CI: 3.6-6.2 months) for all patients and 10.5 months (95% CI: 6.2-15.2 months) for the responders. The median overall survival was 11.2 months (95% CI: 6.5-18.4 months).The mitomycin-C/cisplatin combination showed antitumour activity in the treatment of advanced or recurrent squamous-cell carcinoma of the uterine cervix. The regimen was well tolerated and could be administered on an outpatient basis.
Collapse
Affiliation(s)
- H C Wagenaar
- Department of Gynaecology, Leiden University Medical Center, Department of Gynaecology, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-22. [PMID: 11454878 DOI: 10.1200/jco.2001.19.14.3312] [Citation(s) in RCA: 859] [Impact Index Per Article: 37.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) and topotecan in patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy. PATIENTS AND METHODS Patients with measurable and assessable disease were randomized to receive either PLD 50 mg/m(2) as a 1-hour infusion every 4 weeks or topotecan 1.5 mg/m(2)/d for 5 consecutive days every 3 weeks. Patients were stratified prospectively for platinum sensitivity and for the presence or absence of bulky disease. RESULTS A total of 474 patients were treated (239 PLD and 235 topotecan). They comprised the intent-to-treat population. The overall progression-free survival rates were similar between the two arms (P =.095). The overall response rates for PLD and topotecan were 19.7% and 17.0%, respectively (P =.390). Median overall survival times were 60 weeks for PLD and 56.7 weeks for topotecan. Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from PLD for progression-free survival (P =.037), with medians of 28.9 for PLD versus 23.3 weeks for topotecan. For overall survival, PLD was significantly superior to topotecan (P =.008), with a median of 108 weeks versus 71.1 weeks. The platinum-refractory subgroup demonstrated a nonstatistically significant survival trend in favor of topotecan (P =.455). Severe hematologic toxicity was more common with topotecan and was more likely to be associated with dosage modification, or growth factor or blood product utilization. CONCLUSION The comparable efficacy, favorable safety profile, and convenient dosing support the role of PLD as a valuable treatment option in this patient population.
Collapse
Affiliation(s)
- A N Gordon
- Texas Oncology, Professional Association, Dallas, TX 75246, USA.
| | | | | | | | | | | |
Collapse
|
24
|
Vermorken JB, Zanetta G, De Oliveira CF, van der Burg ME, Lacave AJ, Teodorovic I, Boes GH, Colombo N. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Ann Oncol 2001; 12:967-74. [PMID: 11521804 DOI: 10.1023/a:1011165115426] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with such regimens a higher overall response rate and a higher complete response rate could be obtained compared to what might have been expected from cisplatin alone. In that respect the combination of bleomycin, vindesine (Eldesine), mitomycin C and cisplatin (BEMP) was the most promising. In the present study BEMP has been compared with the best single agent, cisplatin (P) in the expectation that improved response rates might translate into a better survival. PATIENTS AND METHODS Eligible patients were those with SCCUC and disseminated measurable disease outside previously irradiated areas, aged < or = 75 years, with a WHO performance status < or = 2 and adequate bone marrow, renal, hepatic and pulmonary function, who gave consent according to regulations followed in individual institutions. Patients were randomized to BEMP: E 3 mg/m2 day 1, P 50 mg/m2 day 1, B 15 mg (24-hour infusion) day 2-4 and M 8 mg/m2 (at alternate cycles), or P 50 mg/m2. The first four cycles were given every 3 weeks (induction phase). Subsequent cycles were given every four weeks (maintenance phase), during which B was deleted from BEMP (MEP). Patients failing on P could be treated with BEM. Of the 287 patients entered, 235 were eligible and 201 evaluable for response. RESULTS BEMP induced a significantly higher response rate than P (42% vs. 25%, P = 0.006). There was no difference in complete response rate (11% vs. 7%). BEMP was significantly more toxic than P (+/- BEM), both with respect to hematologic and nonhematologic toxicities. After a median follow-up of 6.1 years, survival curves were not significantly different. Median progression-free survival and overall survival were 5.3 and 10.1 months with BEMP and 4.5 and 9.3 months with P (+/- BEM), respectively. In a multivariate analysis of prognostic factors for survival, a lower age (P = 0.003), a lower performance status (P = 0.0001) and a short (<1 year) interval since diagnosis (P = 0.0152) were all associated with an increased risk of dying. For progression-free survival, lower age, prior radiotherapy, locoregional involvement and no prior surgery were associated with a high risk. Treatment with BEMP or P had no significant impact on survival, but for progression-free survival there was a trend in favor of BEMP (P = 0.0893). Adjusting for prognostic factors did not change the effect of treatment. CONCLUSIONS Combination chemotherapy with BEMP produces more toxicity and more responses compared with cisplatin alone in patients with disseminated SCCUC, but this does not translate into a better survival. Therefore, in the palliative setting single-agent cisplatin should remain the standard therapy for these patients.
Collapse
Affiliation(s)
- J B Vermorken
- Department of Oncology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Wagenaar HC, Colombo N, Vergote I, Hoctin-Boes G, Zanetta G, Pecorelli S, Lacave AJ, van Hoesel Q, Cervantes A, Bolis G, Namer M, Lhommé C, Guastalla JP, Nooij MA, Poveda A, Scotto di Palumbo V, Vermorken JB. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecol Oncol 2001; 81:348-54. [PMID: 11371121 DOI: 10.1006/gyno.2001.6180] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To investigate tumor response rate and treatment toxicity of a modified combination chemotherapy consisting of bleomycin (B), methotrexate (M), and CCNU (C) for patients with locally advanced, squamous-cell carcinoma of the vulva (not amenable to resection by standard radical vulvectomy) or recurrent disease (after incomplete resection). Tumor resectability was reassessed in patients who had responded to chemotherapy. METHODS The regimen consisted of bleomycin 5 mg intramuscular (im) days 1-5, CCNU 40 mg per os (po) days 5-7, and methotrexate 15 mg po days 1 and 4 during the first week. During weeks 2-6 the patient was administered bleomycin 5 mg im days 1 and 4, and methotrexate 15 mg po on day 1 of the week. This 6-week cycle was repeated at 49-day intervals. RESULTS Twenty-five eligible patients with a median age of 66 years (range, 39-82 years) were entered in this phase II trial. Twelve patients had primary locally advanced disease, 13 patients had a locoregional recurrence, and all received up to three BMC cycles. Two complete and twelve partial responses were observed (response rate, 56%; 95% confidence limits, 35-76%). The BMC regimen was associated with major hematological side effects and mild signs of bleomycin-related pulmonary toxicity. At a median follow-up of 8 months, 3 patients were alive, 18 had died due to malignant disease, 2 had died due to toxicity, and 2 had died due to intercurrent disease and unknown cause. The median progression-free survival was 4.8 months and the median survival was 7.8 months. The 1-year survival was 32% (95% confidence limits, 13-51%). CONCLUSION The present data confirm the therapeutic activity of the BMC regimen in locoregionally advanced or recurrent squamous-cell carcinoma of the vulva. Following neoadjuvant chemotherapy, the overall response rate was 56%. BMC is an outpatient treatment that may play a role in the palliative therapy of advanced or recurrent vulva cancer.
Collapse
Affiliation(s)
- H C Wagenaar
- Department of Gynaecology, Leiden University Medical Center, Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Duffaud F, van der Burg ME, Namer M, Vergote I, ten Bokkel Huinink W, Guastalla JP, Kerbrat P, Piccart M, Tumolo S, Favalli G, van der Vange N, Lacave AJ, Wils J, Splinter TA, Einhorn N, Roozendaal KJ, Rosso R, Vermorken JB. D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study. Anticancer Drugs 2001; 12:159-62. [PMID: 11261890 DOI: 10.1097/00001813-200102000-00010] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression. No objective responses were observed. Eleven out of 68 evaluable patients (16%) had stable disease. The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients. The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months. The treatment was well tolerated; the only reported adverse events were incidental hot flushes. This study showed that the LHRH agonist Triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy.
Collapse
Affiliation(s)
- F Duffaud
- EORTC Data Centre, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648-57. [PMID: 10894863 DOI: 10.1200/jco.2000.18.14.2648] [Citation(s) in RCA: 382] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
PURPOSE To compare the efficacy and tolerability of etoposide, leucovorin, and bolus fluorouracil (ELF) or infusional fluorouracil plus cisplatin (FUP) with that of the reference protocol of fluorouracil, doxorubicin, and methotrexate (FAMTX) in advanced gastric cancer. PATIENTS AND METHODS A total of 399 patients with advanced adenocarcinoma of the stomach were randomized and analyzed for toxicity, tumor response, and progression-free and overall survival. Only reviewed and confirmed responses were considered. The analysis of remission was based on assessable patients with documented measurable lesions. The intent-to-treat principle, log-rank test, and Cox regression model were used for the statistical analysis of time-to-event end points. RESULTS The overall response rate for 245 eligible patients with measurable disease was 9% with ELF, 20% with FUP, and 12% with FAMTX, with no significant differences. One hundred twelve patients were eligible for efficacy in assessable, nonmeasurable disease. No change was observed in 66% of patients treated with ELF, 56% with FUP, and 55% with FAMTX. Two patients achieved a complete tumor regression (one each for ELF and FAMTX). With a median follow-up time of 4.5 years, the median survival times were 7.2 months with ELF, 7.2 months with FUP, and 6.7 months with FAMTX, respectively, with no significant differences. Nonhematologic and hematologic toxicities of ELF, FUP, and FAMTX were acceptable, with neutropenia being the major toxicity for all three regimens. Seven treatment-related deaths occurred (two with FUP and five with FAMTX). CONCLUSION All three investigated regimens demonstrate modest clinical efficacy and should not be regarded as standard treatment for advanced gastric cancer. New strategies should be considered to achieve a better clinical efficacy in the treatment of advanced gastric cancer.
Collapse
Affiliation(s)
- U Vanhoefer
- Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Esteban E, de Sande G, Puertas J, Fra J, Palacio I, Vieitez JM, Fernández JL, Muñiz I, Modollel A, Carrasco J, Sala M, Lacave AJ. A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Res Treat 2000; 62:127-33. [PMID: 11016750 DOI: 10.1023/a:1006477109230] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND Vinorelbine (Navelbin; N) has proven to be active in patients with advanced breast cancer (ABC) and cyclophosphamide (C) and epirubicin (Epiadriamycin: E) are still among the main cytostatic agents against this tumor. On this basis was carried out a study to determine the activity and toxicity of the combination of these three agents (CEN). PATIENTS AND METHOD From April 1996 to March 1998, 59 patients with ABC were recruited of whom 56 were found eligible and evaluable for toxicity and 55 for activity. The treatment regimen was C: 400 mg/m2, E: 30 mg/m2 and N: 25 mg/m2 administered intravenously on days 1 and 8 of a 28-day cycle. RESULTS The median number of cycles administered was 6 (range: 1-16). The most common hematological toxicity was grade (G) 3 and 4 neutropenia occurring in 36% of patients, associated with fever in 7% of them. Grade 3-4 thrombocytopenia and anemia occurred in 5% and 7%, respectively. Other G2-G3 non hematologic toxicities were: N/vomiting in 34%, alopecia in 73% and mucositis in 11% of patients. An objective response was achieved in 28 of 56 patients (50%) (95% confidence interval (CI): 37-63%): complete response (CR) in 9%, partial response (PR) in 41%. The median duration of response, time to progression and overall survival time was 54, 47 and 90 weeks, respectively. CONCLUSION The CEN combination at these doses and treatment schedule appears to have acceptable tolerability but there is no apparent improvement in therapeutic efficacy when compared to other regimens used as first line treatment in ABC.
Collapse
Affiliation(s)
- E Esteban
- Servicio de Ontología Médica, Hospital Central de Asturias, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D, Van Glabbeke M, Lacombe D, Pinel MC, Pecorelli S. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18:1193-202. [PMID: 10715288 DOI: 10.1200/jco.2000.18.6.1193] [Citation(s) in RCA: 129] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This was a multicentric, open, randomized, phase II study of single-agent paclitaxel and oxaliplatin to evaluate the efficacy of oxaliplatin in a relapsing progressive ovarian cancer patient population and to analyze the safety profile and impact of both agents on quality of life, time to progression, and survival. PATIENTS AND METHODS Eighty-six patients with platinum-pretreated advanced ovarian cancer were randomly assigned to two arms: 41 received paclitaxel at 175 mg/m(2) over 3 hours every 3 weeks, and 45 received oxaliplatin at 130 mg/m(2) over 2 hours every 3 weeks. For inclusion, patients had to have a performance status of 0 to 2 and to have received at least one and no more than two prior cisplatin- and/or carboplatin-containing chemotherapy regimens within the last 12 months. RESULTS Seven confirmed responses were observed in each arm, for an overall response rate in the total treated population of 17% (95% confidence interval [CI], 7% to 32%) in the paclitaxel arm and 16% (95% CI, 7% to 29%) in the oxaliplatin arm. Median time to progression was 14 weeks and 12 weeks, and overall survival was 37 weeks and 42 weeks in the paclitaxel and oxaliplatin arms, respectively. Among 63 patients with a 0- to 6-month progression-free, platinum-free interval, there were five objective responses with paclitaxel in 31 patients and two objective responses with oxaliplatin in 32 patients. Nine patients (22%) in the paclitaxel arm had grade 3 or 4 neutropenia (National Cancer Institute of Canada [NCIC] Common Toxicity Criteria). Two patients (4%) experienced grade 3 thrombocytopenia in the oxaliplatin arm. Maximum grade (grade 3) NCIC neurosensory toxicity was experienced by three patients (7%) in the paclitaxel arm and by four patients (9%) in the oxaliplatin arm. CONCLUSION Single-agent oxaliplatin at 130 mg/m(2) every 3 weeks is active with moderate toxicity in patients with cisplatin-/carboplatin-pretreated advanced ovarian cancer.
Collapse
Affiliation(s)
- M J Piccart
- Institut Jules Bordet and European Organization for Research and Treatment of Cancer, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Estaban E, Lacave AJ, Fernández JL, Corral N, Buesa JM, Estrada E, Palacio I, Vieitez JM, Muñiz I, Alvarez E. Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Res Treat 1999; 58:141-50. [PMID: 10674879 DOI: 10.1023/a:1006387801960] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND The mitoxantrone combination CNF and the epirubicin combination CEF have shown similar activity and less toxicity than the standard CAF combination in metastatic breast cancer (MBC). A prospective randomised study was started to compare safety and activity between CEF and CNF administered using a classical chemotherapeutic schedule in MBC. PATIENTS AND METHODS From December 1987 to June 1993, 151 patients were randomised to receive cyclophosphamide (C) 100 mg m(-2) p.o. days 1-14, fluorouracil (F) 500 mg m(-2) i.v. days 1 and 8, and epirubicin (E) 30 mg m(-2) i.v. days 1 and 8, or mitoxantrone (N) 6 mg m(-2) i.v. days 1 and 8, every 4 weeks. Seventy-three patients were eligible for CEF and 72 for CNF. RESULTS Objective responses were observed in 61.6% of the CEF group and 44.4% in CNF group (p = 0.004). The median duration of response was 64 weeks in CEF and 50 weeks in CNF group (p = 0.02) and median time to progression was 51 and 33 weeks, respectively (p = 0.0004). At the time of analysis, all except six patients (one in CNF and five in CEF) had died and the median survival time in the CEF group was longer than in CNF (74.4 weeks vs 51.4 weeks; log-rank chi2 test p = 0.015). CNF produced more hematologic toxicity than CEF (WHO scale; grades 2-4); leucopenia 84% vs 68% (p = 0.03) and thrombocytopenia 17% vs 4.5% (p = 0.01); CEF caused more grade 2 and 3 alopecia: 93% vs 70% (p = 0.001). CONCLUSION The combination CEF using this schedule and dosage in metastatic breast cancer is more effective with less toxicity than CNF, except for alopecia, and was associated with longer survival.
Collapse
Affiliation(s)
- E Estaban
- Servicio de Oncología Médica, Hospital Central de Asturias, Oviedo, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33:1216-20. [PMID: 9301445 DOI: 10.1016/s0959-8049(97)00088-9] [Citation(s) in RCA: 202] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Patients with measurable or evaluable locally advanced or metastatic squamous cell carcinoma of the oesophagus were treated with cisplatin (CDDP), 100 mg/m2, combined with 5-fluorouracil (5-FU) at a dose of 1000 mg/m2 as a continuous infusion from days 1-5 (Arm A) or with CDDP alone (Arm B). Cycles were repeated every 3 weeks. 92 patients were randomised centrally, 88 were eligible. The response rate was 35% (95% CI (confidence interval), 20-54%) in Arm A and 19% (95% CI, 8-35%) in Arm B. One complete response was observed in each arm. The median duration of survival was 33 weeks and 28 weeks for Arm A and Arm B, respectively. Haematological and non-haematological toxicities were more frequent and more severe in Arm A. The most prominent toxicities were grade 4 aplasia and septicaemia (2), meningeal haemorrhage (1), cerebrovascular accident (3) and ischaemia of the lower limbs (1) all occurring in Arm A. Overall, seven treatment-related deaths (16%) were observed in Arm A, none in Arm B. The severe side-effects induced by the combination suggest that, currently, no standard chemotherapy can be recommended for patients with advanced squamous cell oesophageal cancer.
Collapse
|
32
|
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14:3056-61. [PMID: 8955650 DOI: 10.1200/jco.1996.14.12.3056] [Citation(s) in RCA: 290] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE Topotecan is a topoisomerase I inhibitor with preclinical activity against various tumor types. We conducted a large multicenter phase II study with topotecan in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen. PATIENTS AND METHODS Topotecan 1.5 mg/m2/d was administered intravenously by 30-minute infusion for 5 days repeated every 3 weeks. As the cisplatin-free interval relates to response in subsequent treatment, patients were stratified in subgroups, ie, cisplatin-refractory, cisplatin-resistant, and cisplatin-sensitive. RESULTS One-hundred eleven patients entered the study. Nineteen patients were considered to be ineligible; 92 patients were assessable for response. A total of 552 courses were given (median, four per patient; range, one to 17). The major toxicities were leukocytopenia and neutropenia, which were grade 3 to 4 in 54.2% and 69.1% of courses, respectively, but with only 4.3% of these being grade 4 neutropenia plus fever or infectious complications. Prophylactic granulocyte colony-stimulating factor (G-CSF) was given in 20.5% of courses to maintain dose-intensity. Other relatively frequent side effects were alopecia (82%), nausea (36.4%), and vomiting (17.5%). The overall response rate was 16.3%, with one complete response (CR) and 14 partial responses (PRs). In the cisplatin-refractory, cisplatin-resistant, and cisplatin-sensitive strata, the response rates were 5.9%, 17.8%, and 26.7%, respectively. The median duration of time of documented response was 21.7 weeks (range, 4.6 to 41.9). CONCLUSION Topotecan in a daily-times-five schedule is an effective regimen as second-line treatment in ovarian cancer. Further investigations of topotecan in ovarian cancer, including first-line use and combination with other active agents, are indicated.
Collapse
Affiliation(s)
- G J Creemers
- Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Lacave AJ, Peláez I, Palacio I. Chemotherapy for ovarian cancer. N Engl J Med 1996; 334:1269-70. [PMID: 8606731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
34
|
Peláez I, Lacave AJ, Palacio I, Alvarez E, Cueva JF, Muñiz I, Arranz F, Fra J. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur J Cancer 1996; 32A:899-900. [PMID: 9081375 DOI: 10.1016/0959-8049(96)00003-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
35
|
van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332:629-34. [PMID: 7845426 DOI: 10.1056/nejm199503093321002] [Citation(s) in RCA: 477] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Although the value of primary cytoreductive surgery for epithelial ovarian cancer is beyond doubt, the value of debulking surgery after induction chemotherapy has not yet been defined. In this randomized study we investigated the effect on survival of debulking surgery. METHODS Eligible patients had residual lesions measuring more than 1 cm in diameter after primary surgery. After three cycles of cyclophosphamide and cisplatin, these patients were randomly assigned to undergo either debulking surgery or no surgery, followed by further cycles of cyclophosphamide and cisplatin. The study end points were progression-free and overall survival. At surgery 65 percent of the patients had lesions measuring more than 1 cm. In 45 percent of this group, the lesions were reduced surgically to less than 1 cm. RESULTS Of the 319 patients who underwent randomization, 278 could be evaluated (140 patients who underwent surgery and 138 patients who did not). Progression-free and overall survival were both significantly longer in the group that underwent surgery (P = 0.01). The difference in median survival was six months. The survival rate at two years was 56 percent for the group that underwent surgery and 46 percent for the group that did not. In the multivariate analysis, debulking surgery was an independent prognostic factor (P = 0.012). Overall, after adjustment for all other prognostic factors, surgery reduced the risk of death by 33 percent (95 percent confidence interval, 10 to 50 percent; P = 0.008). Surgery was not associated with death or severe morbidity. CONCLUSIONS Debulking surgery significantly lengthened progression-free and overall survival. The risk of death was reduced by one third, after adjustment for a variety of prognostic factors.
Collapse
Affiliation(s)
- M E van der Burg
- Rotterdam Cancer Institute, Daniel den Hoed Kliniek, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Neijt JP, Lacave AJ, Splinter TA, Taal BG, Veenhof CH, Sahmoud T, Lips CJ. Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. Br J Cancer 1995; 71:106-8. [PMID: 7819024 PMCID: PMC2033476 DOI: 10.1038/bjc.1995.21] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
We performed a phase II study with mitoxantrone in patients with carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid. Thirty-five eligible patients received mitoxantrone 12 mg m-2 i.v. every 3 weeks. Among 18 previously untreated patients, three responded (17%, 95% CI = 4-41%); no responses were achieved in 17 previously treated patients. Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%). Overall response rate was 9% (95% CI = 2-23%). At a median follow-up of 43 months, median overall survival was 16 months. The median survival of 21 patients with a normal alkaline phosphatase was 29 months and 9 months for 14 patients with elevated serum levels (P = 0.005). A similar observation was noticed for gamma-glutamyltransferase (P = 0.007). We concluded that mitoxantrone is not active in APUD tumours. Elevated alkaline phosphatase and gamma-glutamyltransferase are associated with a poor prognosis.
Collapse
Affiliation(s)
- J P Neijt
- Department of Internal Medicine, Utrecht University Hospital, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
37
|
Peláez I, López R, Palacio I, Fernández Y, Estrada E, Esteban E, Buesa JM, Lacave AJ. Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer. Eur J Cancer 1994; 30A:1206-7. [PMID: 7654459 DOI: 10.1016/0959-8049(94)90490-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
38
|
|
39
|
Constela M, Barón FJ, Rubiales AS, Barrajón E, Calvo L, Otero J, Mel JR, Cueva J, Lacave AJ. Phase II trial of 5-fluorouracil(F), etoposide (E) and cisplatin (P) in 5 days (FEP-5) for advanced gastric cancer (GC). Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91205-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Palacio I, Fernández Y, Peláez I, Cueva J, Esteban E, Estrada E, Buesa JM, Lacave AJ. Negative phase II with 5-fluorouracil (5-FU) plus low doses of leucovorin (LV) in refractory breast carcinoma(RBC). Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91083-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Van der Burg MEL, Van Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Buyse M, Pecorelli S. Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC); an EORTC gynecological cancer cooperative group (GCCG) study. Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91344-k] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Palacio I, Buesa JM, De Sande L, Cueva JF, Esteban E, Estrada E, Gracia JM, Lacave AJ. Negative phase II study with carboplatin and 5-fluorouracil in advanced breast cancer. Eur J Cancer 1992; 28:242. [PMID: 1567669 DOI: 10.1016/0959-8049(92)90417-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
43
|
Lacave AJ, Barón FJ, Antón LM, Estrada E, De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernández OA. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991; 2:751-4. [PMID: 1801881 DOI: 10.1093/oxfordjournals.annonc.a057858] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Fifty-six patients with measurable or evaluable advanced gastric cancer were treated with cisplatin, 100 mg/m2 in continuous infusion of 24 hours, and 5-fluorouracil, 1000 mg/m2/day (by continuous 5-day infusion) every 4 weeks. Three patients were found ineligible for the study. A response rate of 41% (22/53) was obtained (95% confidence interval: 28%-54%), with a median duration of remission of 10.2 months and an overall median survival time of 10.6 months. Leukopenia and thrombocytopenia were mild. Nausea and vomiting were common, and 23.5% of the patients had grade 3 stomatitis. Peripheral neuropathy and renal insufficiency increased with the number of cycles, representing the cumulative dose-limiting toxicity. This study indicates that the combination of cisplatin plus 5-fluorouracil is synergistic or at least has additive antitumor activity. We think that this association of 2 drugs should be considered for further phase III clinical trials.
Collapse
Affiliation(s)
- A J Lacave
- Servicio de Oncología Médica, Hospital General de Asturias, Oviedo, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Palacio I, Buesa JM, Barón FJ, López R, Cueva JF, Esteban E, Estrada E, Gracia JM, Lacave AJ. Inefficiency of cisplatin plus 5-FU as second-or third line treatment in advanced breast cancer. Ann Oncol 1991; 2:521. [PMID: 1911462 DOI: 10.1093/oxfordjournals.annonc.a058008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
|
45
|
Buesa JM, Fernández R, Esteban E, Estrada E, Barón FJ, Palacio I, Gracia M, Lacave AJ. Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 1991; 2:151-2. [PMID: 1905150 DOI: 10.1093/oxfordjournals.annonc.a057880] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Thirty-six patients with recurrent carcinoma of the head and neck and no prior exposure to chemotherapy were treated with Ifosfamide. This drug was administered, concomitantly with Mesna, as a 24-hr infusion at a dose of 5-6.25 g/m2 every 3 weeks. Objective activity in 32 evaluable patients was 28% (9/32, 95% C.I. 17%-39%); 40% of patients had leukocyte values less than 2000 mm3 and 6% platelets less than 50,000 mm3. Nonhematologic toxicity consisted mainly of nausea/vomiting (66% greater than or equal to grade 2) and alopecia (80% greater than or equal to grade 2). The activity encountered warrants further studies with this drug in head and neck cancer.
Collapse
Affiliation(s)
- J M Buesa
- Servicio de Oncología Médica, Hospital General de Asturias, Oviedo, Spain
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Durrant KR, Mangioni C, Lacave AJ, George M, van der Burg ME, Guthrie D, Rotmenz N, Dalesio O, Vermorken JB. Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG). Gynecol Oncol 1990; 37:359-62. [PMID: 1693584 DOI: 10.1016/0090-8258(90)90367-t] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- K R Durrant
- Department of Radiotherapy and Oncology, Churchill Hospital, Headington, Oxford, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Fernández Hidalgo O, González F, Gil A, Campbell W, Barrajón E, Lacave AJ. 120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol 1989; 12:397-401. [PMID: 2801599 DOI: 10.1097/00000421-198910000-00007] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAF or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU). Objective response was demonstrated in 19 patients (52.7%), stable disease in 7 patients (19.4%) and progression of the disease in 10 patients (27.7%). Similar response rate was observed according to tumor site (soft tissues, 50%; bone, 52%; lung, 63%; liver, 55%; and pleura and peritoneum, 42%) and previous treatment (previous chemotherapy, 48%; previously untreated, 61%). Median duration of response was 8 months. Toxicity was characterized by stomatitis and myelodepression and required dose adjustments in 30% of patients. CDDP and 5-FU infusion deserve further investigation because it appeared to have substantial activity in this preliminary study in metastatic breast cancer.
Collapse
|
48
|
Lacave AJ, Wils J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H, Duez N, Dalesio O. cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer Clin Oncol 1985; 21:1321-4. [PMID: 4076293 DOI: 10.1016/0277-5379(85)90311-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Thirty-four patients with measurable metastatic gastric adenocarcinoma refractory to prior chemotherapy were treated with cis-platinum 100 mg/m2 in a 6-hr infusion at 3-week intervals. Thirty-one patients were evaluable for response. There were three complete and three partial responses. Median duration of response was 4 months. Toxicity consisted mainly of nausea and vomiting and was severe in 12 patients. One patient had a severe but reversible renal failure. These results confirm other data reported in the literature. Cis-platinum has activity in gastric adenocarcinoma and should now be further investigated in first-line chemotherapy.
Collapse
|
49
|
Vermorken JB, Armand JP, Lacave AJ, George M, de Oliveira CF, Cheix F, Maskens AP, Rotmensz N. Phase II trial of bleomycin in patients with advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study. Eur J Cancer Clin Oncol 1985; 21:671-3. [PMID: 2410278 DOI: 10.1016/0277-5379(85)90263-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Bleomycin was administered by continuous i.v. infusion at a dose of 20 mg/m2/day for 7 days to 18 evaluable patients with advanced ovarian epithelial cancer resistant to conventional chemotherapy. The toxicity pattern was no different from that known from earlier studies using continuous infusion of bleomycin with the exception of the occurrence of a life-threatening allergic reaction in one patient, which led to discontinuation of treatment after 3 days. Only one patient showed a partial response for 2 months (5.5%), indicating that the drug has no significant activity in this unfavorable group of patients.
Collapse
|
50
|
Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ. Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep 1984; 68:499-504. [PMID: 6704980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A phase I study was conducted with dacarbazine (DTIC) protected from light and administered iv as a single dose every 3 weeks. Eighteen patients received 47 courses of DTIC, with doses ranging from 850 to 1980 mg/m2. Hypotension was the dose-limiting toxic effect and it may be secondary to the citric acid present in the pharmaceutic preparation of DTIC. Sporadic myelosuppression was seen at doses greater than 1380 mg/m2. Other side effects noted were nausea and vomiting, acute diarrhea, headache, a "flu-like" syndrome, and a hypersensitivity reaction to sunlight. No antitumor activity was found. The results of this study indicate that this may be a qualitatively different way of giving DTIC, and that the side effects of this drug may be intermingled with those of citric acid in this particular schedule. If the conventional pharmaceutic preparation of this drug is not modified, further studies with high-dose DTIC protected from light should be discouraged.
Collapse
|